Healthcare
Laxmi Dental Limited (NSE: Laxmidentl) Q4 FY26: Revenue Up 21.9%, PAT Surges 136.1%
Laxmi Dental Limited (NSE: LAXMIDENTL) announces Q4 FY26 results with 21.9% YoY revenue growth, PAT up 136.1%.
Laxmi Dental Limited (NSE: LAXMIDENTL) announced its audited financial results for the quarter and full year ended March 31st, 2026, showcasing a robust performance across key metrics. The company reported its highest-ever quarterly revenue with a 21.9% year-over-year growth, reaching INR 739.5 crore for Q4 FY26. The Profit After Tax (PAT) surged by 136.1% to INR 100.9 crore.
Q4 FY26 Performance Highlights
The quarter saw significant achievements including:
- Highest-ever quarterly revenue of INR 739.5 crore.
- EBITDA margin of 18.3%, up from 15.7% in Q4 FY25.
- PAT margin of 13.6%, a notable increase from 7.0% in the same quarter last year.
Full Year FY26 Performance
For the full year, Laxmi Dental Limited posted a revenue of INR 2,778.6 crore, marking a 16.2% growth year-over-year. Despite macroeconomic challenges and geopolitical situations, the company maintained a healthy margin profile. Key highlights include:
- EBITDA margin of 15.6%.
- PAT margin of 10.4%.
- Adjusted EBITDA of INR 511.5 crore, down slightly by 0.9% from the previous year.
Management expressed optimism about the future, emphasizing continued efforts towards digitalization and business expansion. With digital penetration levels for the Indian Dental business at ~80%, the company is well-positioned to capitalize on the growing demand for dental products.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Laxmi Dental Limited
Laxmi Dental Limited belongs to the Healthcare › Medical Instruments & Supplies sector. Here’s a quick read on where the business and the stock stand today.
Laxmi trades in the lower quarter of its 52-week range. Thin margins at 8.8% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock sits at 15% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 22.3% and profits at 0.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Laxmi Dental Limited.
Healthcare
Natco Pharma Limited Receives Positive FDA Inspection Report for Visakhapatnam Plant
Natco Pharma Limited (NSE: NATCOPHARM) receives positive FDA inspection report for Visakhapatnam plant, classifying it as Voluntary Action Indicated (VAI).
Natco Pharma Limited (NSE: NATCOPHARM) announced today the receipt of a positive Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Visakhapatnam plant. The inspection, conducted from August 17th to August 21st, 2026, resulted in the classification of the inspection as Voluntary Action Indicated (VAI), indicating minor observations. The company received four observations in the Form 483 during the inspection.
Positive Outcome
The positive outcome of the FDA inspection is a significant milestone for Natco Pharma Limited, reinforcing the company’s commitment to maintaining high standards in its manufacturing processes. The classification as VAI suggests that while there are minor areas for improvement, the overall compliance with regulatory standards is satisfactory.
Commitment to Quality
Natco Pharma Limited continues to prioritize quality and regulatory compliance in its operations. The company’s manufacturing facilities are approved by several leading regulatory authorities, including the U.S. FDA, Brazil ANVISA, Health Canada, and WHO, serving over 50 global markets. The positive FDA report further solidifies the company’s reputation for producing high-quality pharmaceuticals.
Natco Pharma Limited remains dedicated to its mission of developing, manufacturing, and distributing generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients, and crop protection products. The company’s R&D-oriented approach and science-driven focus enable it to lead in targeted therapies, particularly in oncology, both domestically and internationally.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Natco Pharma Limited
Natco Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Natco trades in the lower quarter of its 52-week range. The PEG of 0.70 signals undervaluation relative to growth. It is a potential re-rating candidate. Industry-leading margins of 26.8% reflect exceptional pricing power and operational efficiency. Buyers show up with 1.9x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. Revenue grows at 14.5% and profits at 25.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 7.6% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Natco Pharma Limited.
BETA
Beta Drugs Limited Forms Oncology Joint Venture with IMGSA Groupe SPA
Beta Drugs Limited forms oncology joint venture with IMGSA Groupe SPA, acquiring oncology plant for US$8.7 million.
Beta Drugs Limited (“Beta”) today announced that it has entered into a joint venture (“JV”) with IMGSA Groupe SPA (“IMGSA”), a leading pharmaceutical company in Algeria. Beta will hold a 49% stake in the JV, acquiring IMGSA’s oncology formulation plant for US$8.7 million. This strategic move aims to deepen the partnership and build a strong oncology business in Algeria and North African markets.
Transaction Details
The JV will acquire the oncology plant from IMGSA for US$8.7 million. Part of the consideration will be settled by issuing equity shares to IMGSA. Beta will infuse US$3 million over three years and transfer formulation technology to the JV. The plant has manufacturing capabilities for both injectable and oral solid dosage forms, enabling the JV to produce a range of oncology products locally in Algeria.
Market Positioning
The Algerian oncology market is valued at approximately US$1 billion and growing rapidly. The JV is well positioned to capture significant market share in national tenders by combining Beta’s research, development, manufacturing, and supply chain capabilities with IMGSA’s marketing and distribution infrastructure. The Algerian government incentivizes local manufacturing of critical life-saving pharmaceutical products, further supporting the JV’s growth.
Rahul Batra, MD of Beta Drugs Limited, said: “Our relationship with IMGSA has grown steadily over many years, and this joint venture marks a natural next step for us to deepen our relationship and commitment to the Algerian market. By bringing our manufacturing technology and know-how to a well-equipped oncology plant and pairing it with IMGSA’s strong market presence in Algeria, we aim to improve access to quality cancer therapies for patients in Algeria.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Beta Drugs Limited
Beta Drugs Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Beta falls 25.9% over three months and has not found a floor yet. The PEG reaches 3.48. The stock trades on brand and index weight, not on growth. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 4.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 19.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Beta Drugs Limited.
Health Information Services
Indegene Limited (indgn) Becomes First Industry Partner of Indo-uk Life Science Corridor
Indegene Limited (INDGN) announced as the first industry partner for the Indo-UK Life Science Corridor, connecting India and UK research.
Indegene Limited (INDGN) has been announced as the first industry partner for the Indo-UK Life Science Corridor, a collaboration between the Centre for Cellular and Molecular Platforms (C-CAMP) and Imperial College London. This initiative, supported by the Imperial Global India initiative, aims to connect world-class research in India and the UK with entrepreneurship, industry expertise, and pathways to translation. The corridor is designed to facilitate the two-way sharing of knowledge and evidence on priority challenges, innovation readiness, and ecosystem needs.
Strategic Collaboration
Indegene, C-CAMP, and Imperial College London will co-develop entrepreneurship programs and support the exchange of knowledge and talent between India and the UK. Indegene, an AI-native operating partner for modern life sciences, brings deep industry context to the corridor and has a track record of working with the world’s top 20 biopharma companies. As part of the collaboration, Indegene will help define industry challenges and support startup exchanges and ecosystem immersion programs.
Focus Areas
Initial focus areas include antimicrobial resistance, diagnostics, digital health, agritech, brain science, and mental health. The three organizations made the announcement at the C-CAMP–Imperial joint Roundtable on International Partnerships for AI Discovery and Innovation, convened under the Government of Karnataka’s Global Innovation Alliance initiative as part of the Bengaluru Tech Summit 2026.
The partnership reflects Indegene’s commitment to support deep science, strengthen translation pathways, and help promising innovation reach scale. This collaboration is expected to produce smarter, more scalable, and more accessible innovations relevant to both populations.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indegene Limited
Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
Indegene gains 15.9% over three months and trades near its 52-week highs. The PEG of 2.41 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gives back 2.0% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 15.9% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.
-
Health Information Services3 days agoIndegene Limited (indgn) Becomes First Industry Partner of Indo-uk Life Science Corridor
-
FSL2 days agoFirstsource Solutions Limited (FSL) Partners with Sew.ai to Launch Smart Revenue Operations and Collections
-
Apparel Retail3 days agoArvind Fashions Limited: U.S. Polo Assn. Aims for ₹4,000 Crore Sales in FY27
-
DREAMFOLKS3 days agoDreamfolks Strengthens its Southeast Asia Presence, Showcasing Travel & Lifestyle Experiences at Singapore Fintech Festival 2026
-
GREENPOWER3 days agoOrient Green Power Company Limited (NSE: Greenpower) Wins ₹12.98 Crore Recovery in Legal Battle
-
Basic Materials2 days agoValiant Organics Limited Q2 FY27 Earnings Presentation: Robust Growth in Revenue and Profit
-
RAMCOSYS2 days agoRamco Systems Limited Goes Live with Canadian Coast Guard’s Aviation Software
-
AWFIS3 days agoAwfis Space Solutions Limited (awfis) Strengthens Leadership Team with Kumar Alok Gupta as Chief Business Officer National
